SCHEMBL20522284

SCHEMBL20522284

O=S(=O)(NCCCl)c1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
PKM P14618 1/20 0.70
TAAR1 Q96RJ0 1/20 0.60
LMNA P02545 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
MAPT P10636 1/20 0.56
GAA P10253 1/20 0.55
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
CYP19A1 P11511 1/20 0.53
TSHR P16473 1/20 0.53
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
CA9 Q16790 1/20 0.51
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20522373 0.92 ALDH1A1 (0.60) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL7023027 0.82 TSHR (0.64) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL4182181 0.81 CYP3A4 (0.70) LMNACA1CA2TSHRMMP1
SCHEMBL1504601 0.81 ALDH1A1 (0.66) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL8970754 0.81 ALDH1A1 (0.70) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL1148907 0.81 ALDH1A1 (0.70) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL3279019 0.81 ALDH1A1 (0.70) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL28208392 0.81 ALDH1A1 (0.70) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL14046920 0.81 ALDH1A1 (0.70) ALDH1A1MEN1KMT2APKMTAAR1
SCHEMBL26213014 0.81 TDO2 (0.48) ALDH1A1MEN1KMT2APKMTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 ALDH1A1 1183/4885MEN1 3715/4885KMT2A 3101/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1681/4885MEN1 4443/4885KMT2A 2829/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS ALDH1A1 1490/4885MEN1 4170/4885KMT2A 2908/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 ALDH1A1 1415/4885MEN1 4216/4885KMT2A 2772/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1184/4885MEN1 4169/4885KMT2A 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.